News
Michigan public health leaders and research scientists say the fallout from Trump administration cuts to federal research programs hits hard.
47m
MyChesCo on MSNENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast CancerThe Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results